Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Ain Shams University | OTHER |
Not provided
Not provided
Not provided
Heart failure is considered one of the greatest challenges globally. There are various treatment strategies for heart failure. L-Arginine is an amino acid that was found to have beneficial effect on vasculature. This study aims to study the benefits and side effects of using L-arginine on the patients with ejection fraction <40%
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| L-Arginine Arm | Active Comparator | Patients in this arm will be administered 6 gm L-arginine per day |
|
| Placebo Arm | Placebo Comparator | Patients in this arm will take 6 gm placebo per day |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| L-Arginine Powder | Drug | L-arginine 3 gm sachets are used twice daily |
| |
| Measure | Description | Time Frame |
|---|---|---|
| Change of Global longitudinal strain value (GLS) of HF patients from the baseline | 6 weeks |
| Measure | Description | Time Frame |
|---|---|---|
| Change of heart failure symptoms as determined by NYHA classification from baseline | 6 weeks | |
| Change of the functional abilities (ECG) of the patients as determined by the exercise test from baseline | 6 weeks |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Sara Araby, Msc | Contact | +201008662223 | sara.araby96@gmail.com | |
| Mohamed Solayman, PhD | Contact | +201005882550 | mohamed.solayman@guc.edu.eg |
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Ain Shams University | Cairo | Egypt |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D006333 | Heart Failure |
| ID | Term |
|---|---|
| D006331 | Heart Diseases |
| D002318 | Cardiovascular Diseases |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Placebo |
| Drug |
2 sachets of placebo are administered per day |
|
| Changes in biomarkers of heart failure as determined by the difference in NT-proBNP levels from baseline | 6 weeks |
| Change in quality of life between 2 groups as determined by Minnesota Living with Heart Failure questionnaire | 6 weeks |
| Safety profile of the L-Arginine as determined by the change in the mean arterial pressure (MAP) between the 2 groups | 6 weeks |
| Change in biomarkers of endothelial dysfunction as determined by the difference in levels of endothelin-1 | 6 weeks |
| Change in biomarkers of endothelial dysfunction as determined by the difference in levels of Asymmetric dimethylarginine (ADMA) | 6 weeks |
| Safety profile of the L-Arginine as determined by the change in the heart rate (HR) between the 2 groups | 6 weeks |